{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T16:34:45Z","timestamp":1758126885163},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,3,5]],"date-time":"2014-03-05T00:00:00Z","timestamp":1393977600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s11033-014-3246-y","type":"journal-article","created":{"date-parts":[[2014,3,4]],"date-time":"2014-03-04T10:16:17Z","timestamp":1393928177000},"page":"3801-3812","source":"Crossref","is-referenced-by-count":5,"title":["Synergistic anticancer activity of valproate combined with nicotinamide enhances anti-proliferation response and apoptosis in MIAPaca2 cells"],"prefix":"10.1007","volume":"41","author":[{"given":"Hanieh","family":"Jafary","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahin","family":"Ahmadian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masoud","family":"Soleimani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,3,5]]},"reference":[{"issue":"6","key":"3246_CR1","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1158\/1535-7163.MCT-09-1146","volume":"9","author":"S Batra","year":"2010","unstructured":"Batra S, Sahu RP, Kandala PK, Srivastava SKh (2010) Benzyl isothiocyanate-mediated inhibition of histone deacetylase leads to NF-kappaB turnoff in human pancreatic carcinoma cells. Mol Cancer Ther 9(6):1596\u20131608","journal-title":"Mol Cancer Ther"},{"key":"3246_CR2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1476-4598-7-64","volume":"7","author":"R Hamacher","year":"2008","unstructured":"Hamacher R, Schmid RM, Saur D, Schneider G (2008) Apoptotic pathways in pancreatic ductal adenocarcinoma. Mol Cancer 7:64","journal-title":"Mol Cancer"},{"issue":"8","key":"3246_CR3","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3748\/wjg.v19.i8.1173","volume":"19","author":"I Koutsounas","year":"2013","unstructured":"Koutsounas I, Giaginis C, Theocharis S (2013) Histone deacetylase inhibitors and pancreatic cancer: are there any promising clinical trials? World J Gastroenterol 19(8):1173\u20131181","journal-title":"World J Gastroenterol"},{"issue":"4","key":"3246_CR4","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/MPA.0b013e3181c15963","volume":"39","author":"E Deer","year":"2010","unstructured":"Deer E, Gonzales-Hernandez J, Coursen J, Shea J, Ngatia J, Scaifa C, Firpo M, Mulvihill S (2010) Phenotype and genotype of pancreatic cancer cell lines. Pancreas 39(4):425\u2013435","journal-title":"Pancreas"},{"issue":"1","key":"3246_CR5","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1158\/1078-0432.CCR-06-0914","volume":"13","author":"NB Arnold","year":"2007","unstructured":"Arnold NB, Arkus N, Gunn J, Korc M (2007) The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer. Clin Cancer Res 13(1):18\u201326","journal-title":"Clin Cancer Res"},{"issue":"4\u20135","key":"3246_CR6","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1159\/000151537","volume":"8","author":"I Hernandez-Munoz","year":"2008","unstructured":"Hernandez-Munoz I, Skoudy A, Real FX, Navarro P (2008) Pancreatic ductal adenocarcinoma: cellular origin, signaling pathways and stroma contribution. Pancreatology 8(4\u20135):462\u2013469","journal-title":"Pancreatology"},{"issue":"2","key":"3246_CR7","first-page":"e16958","volume":"6","author":"S Iwahashi","year":"2011","unstructured":"Iwahashi S, Shimada M, Utsunomiya T, Morine Y, Imura S, Ikemoto T, Mori H, Hanaoka J, Sugimoto K, Saito Y (2011) Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-a on pancreatic cancer cells. Int J Clin Oncol 6(2):e16958","journal-title":"Int J Clin Oncol"},{"key":"3246_CR8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1479-5876-5-49","volume":"5","author":"MT Buckley","year":"2007","unstructured":"Buckley MT, Yoon J, Yee H, Chiriboga L, Liebes L, Ara G, Qian X, Bajorin DF, Sun TT, Wu XR, Osman I (2007) The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo. J Transl Med 5:49","journal-title":"J Transl Med"},{"issue":"3","key":"3246_CR9","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/bfgp\/elt002","volume":"12","author":"T Bartke","year":"2013","unstructured":"Bartke T, Borgel J, Dimaggio PA (2013) Proteomics in epigenetics: new perspectives for cancer research. Brief Funct Genomics 12(3):205\u2013218","journal-title":"Brief Funct Genomics"},{"issue":"2","key":"3246_CR10","first-page":"170","volume":"5","author":"M Ageberg","year":"2013","unstructured":"Ageberg M, Rydstrom K, Relander T, Drott K (2013) The histone deacetylase inhibitor valproic acid sensitizes diffuse large B-cell lymphoma cell lines to CHOP-induced cell death. Am J Transl Res 5(2):170\u2013183","journal-title":"Am J Transl Res"},{"issue":"6","key":"3246_CR11","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1158\/1535-7163.MCT-08-0860","volume":"8","author":"L Ellis","year":"2009","unstructured":"Ellis L, Atadja PW, Johnstone RW (2009) Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther 8(6):1409\u20131420","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"3246_CR12","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.3390\/ph3082441","volume":"3","author":"L Ellis","year":"2010","unstructured":"Ellis L, Pili R (2010) Histone deacetylase inhibitors: advancing therapeutic strategies in hematological and solid malignancies. Pharmaceuticals (Basel) 3(8):2411\u20132469","journal-title":"Pharmaceuticals (Basel)"},{"issue":"2","key":"3246_CR13","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2353\/jmoldx.2008.070115","volume":"10","author":"G Feldmann","year":"2008","unstructured":"Feldmann G, Maitra A (2008) Molecular genetics of pancreatic ductal adenocarcinomas and recent implications for translational efforts. J Mol Diagn 10(2):111\u2013122","journal-title":"J Mol Diagn"},{"issue":"6","key":"3246_CR14","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ijdevneu.2013.02.005","volume":"31","author":"MJ Morris","year":"2013","unstructured":"Morris MJ, Monteggia LM (2013) Unique functional roles for class I and class II histone deacetylases in central nervous system development and function. Int J Dev Neurosci 31(6):370\u2013381","journal-title":"Int J Dev Neurosci"},{"issue":"4","key":"3246_CR15","doi-asserted-by":"crossref","first-page":"523","DOI":"10.4161\/cbt.7.4.5480","volume":"7","author":"M Ouaissi","year":"2008","unstructured":"Ouaissi M, Cabral S, Tavares J, da Silva AC, Mathieu Daude F, Mas E, Bernard J, Sastre B, Lombardo D, Ouaissi A (2008) Histone deacetylase (HDAC) encoding gene expression in pancreatic cancer cell lines and cell sensitivity to HDAC inhibitors. Cancer Biol Ther 7(4):523\u2013531","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"3246_CR16","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/ijc.22558","volume":"121","author":"T Kumagai","year":"2007","unstructured":"Kumagai T, Wakimoto N, Yin D, Gery S, Kawamata N, Takai N, Komatsu N, Chumakov A, Imai Y, Koeffler HP (2007) Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int J Cancer 121(3):656\u2013665","journal-title":"Int J Cancer"},{"issue":"8","key":"3246_CR17","first-page":"2505","volume":"8","author":"C Aghajanian","year":"2002","unstructured":"Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ, Sabbatini P, Miller V, Hensley ML, Pezzulli S, Canales C, Daud A, Spriggs DR (2002) A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8(8):2505\u20132511","journal-title":"Clin Cancer Res"},{"issue":"4","key":"3246_CR18","first-page":"1351","volume":"33","author":"E Horing","year":"2013","unstructured":"Horing E, Podlech O, Silkenstedt B, Rota IA, Adamopoulou E, Naumann U (2013) The histone deacetylase inhibitor trichostatin a promotes apoptosis and antitumor immunity in glioblastoma cells. Anticancer Res 33(4):1351\u20131360","journal-title":"Anticancer Res"},{"key":"3246_CR19","first-page":"47","volume":"7","author":"K Ververis","year":"2013","unstructured":"Ververis K, Hiong A, Karagiannis TC, Licciardi PV (2013) Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biol Targets Ther 7:47\u201360","journal-title":"Biol Targets Ther"},{"issue":"12","key":"3246_CR20","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1002\/cncr.21589","volume":"104","author":"G Bug","year":"2005","unstructured":"Bug G, Ritter M, Wassmann B, Schoch C, Heinzel T, Schwarz K, Romanski A, Kramer OH, Kampfmann M, Hoelzer D, Neubauer A, Ruthardt M, Ottmann OG (2005) Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer 104(12):2717\u20132725","journal-title":"Cancer"},{"issue":"6","key":"3246_CR21","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2217\/epi.10.62","volume":"2","author":"G Franci","year":"2010","unstructured":"Franci G, Miceli M, Altucci L (2010) Targeting epigenetic networks with polypharmacology: a new avenue to tackle cancer. Epigenomics 2(6):731\u2013742","journal-title":"Epigenomics"},{"issue":"7","key":"3246_CR22","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.3324\/haematol.2009.008870","volume":"95","author":"M Bartels","year":"2010","unstructured":"Bartels M, Geest CR, Bierings M, Buitenhuis M, Coffer PJ (2010) Histone deacetylase inhibition modulates cell fate decisions during myeloid differentiation. Haematologica 95(7):1052\u20131060","journal-title":"Haematologica"},{"key":"3246_CR23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1471-2490-12-21","volume":"12","author":"TK Byler","year":"2012","unstructured":"Byler TK, Leocadio D, Shapiro O, Bratslavsky G, Stodgell CJ, Wood RW, Messing EM, Reeder JE (2012) Valproic acid decreases urothelial cancer cell proliferation and induces thrombospondin-1 expression. BMC Urol 12:21","journal-title":"BMC Urol"},{"issue":"25","key":"3246_CR24","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1200\/JCO.2006.09.4169","volume":"25","author":"W Blum","year":"2007","unstructured":"Blum W, Klisovic RB, Hackanson B, Liu Z, Liu S, Devine H, Vukosavljevic T, Huynh L, Lozanski G, Kefauver C, Plass C, Devine SM, Heerema NA, Murgo A, Chan KK, Grever MR, Byrd JC, Marcucci G (2007) Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 25(25):3884\u20133891","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"3246_CR25","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00277-005-0026-8","volume":"84","author":"A Kuendgen","year":"2005","unstructured":"Kuendgen A, Knipp S, Fox F, Strupp C, Hildebrandt B, Steidl C, Germing U, Haas R, Gattermann N (2005) Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. Ann Hematol 84(Suppl 1):61\u201366","journal-title":"Ann Hematol"},{"issue":"5","key":"3246_CR26","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1002\/cncr.21725","volume":"106","author":"A Morotti","year":"2006","unstructured":"Morotti A, Cilloni D, Messa F, Arruga F, Defilippi I, Carturan S, Catalano R, Rosso V, Chiarenza A, Pilatrino C, Guerrasio A, Taulli R, Bracco E, Pautasso M, Baraban D, Gottardi E, Saglio G (2006) Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leukemia cells. Cancer 106(5):1188\u20131196","journal-title":"Cancer"},{"key":"3246_CR27","author":"M Federico","year":"2011","unstructured":"Federico M, Bagella L (2011) Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors. J Biomed Biotechnol. doi: 10.1155\/2011\/475641","journal-title":"J Biomed Biotechnol"},{"issue":"1","key":"3246_CR28","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2141.2008.07426.x","volume":"144","author":"AB Bouzar","year":"2009","unstructured":"Bouzar AB, Boxus M, Defoiche J, Berchem G, Macallan D, Pettengell R, Willis F, Burny A, Lagneaux L, Bron D, Chatelain B, Chatelain C, Willems L (2009) Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol 144(1):41\u201352","journal-title":"Br J Haematol"},{"issue":"1","key":"3246_CR29","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1188\/13.CJON.34-40","volume":"17","author":"E Glass","year":"2013","unstructured":"Glass E, Viale PH (2013) Histone deacetylase inhibitors: novel agents in cancer treatment. Clin J Oncol Nurs 17(1):34\u201340","journal-title":"Clin J Oncol Nurs"},{"issue":"3","key":"3246_CR30","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s12185-013-1290-3","volume":"97","author":"T Hideshima","year":"2013","unstructured":"Hideshima T, Anderson KC (2013) Histone deacetylase inhibitors in the treatment for multiple myeloma. Int J Hematol 97(3):324\u2013332","journal-title":"Int J Hematol"},{"issue":"3","key":"3246_CR31","first-page":"555","volume":"16","author":"C Yu","year":"2008","unstructured":"Yu C, Chen BA, Gao C, Ding JH, Xia GH, Shao ZY, Gao F, Sun YY, Cheng J, Zhao G, Wang J, Song HH, Ma Y, Bao Wv (2008) Sodium valproate synergizes adriamycin to inhibit proliferation and induce apoptosis in myelodysplastic syndrome cell line. Zhongguo Shi Yan Xue Ye Xue Za Zhi 16(3):555\u2013560","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"7255","key":"3246_CR32","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nature08197","volume":"460","author":"T Finkel","year":"2009","unstructured":"Finkel T, Deng CX, Mostoslavsky R (2009) Recent progress in the biology and physiology of sirtuins. Nature 460(7255):587\u2013591","journal-title":"Nature"},{"issue":"1","key":"3246_CR33","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1158\/0008-5472.CAN-09-2465","volume":"70","author":"M Galli","year":"2010","unstructured":"Galli M, Van Gool F, Rongvaux A, Andris F, Leo O (2010) The nicotinamide phosphoribosyltransferase: a molecular link between metabolism, inflammation, and cancer. Cancer Res 70(1):8\u201311","journal-title":"Cancer Res"},{"issue":"43","key":"3246_CR34","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1038\/onc.2011.612","volume":"31","author":"V Byles","year":"2012","unstructured":"Byles V, Zhu L, Lovaas JD, Chmilewski LK, Wang J, Faller DV, Dai Y (2012) SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis. Oncogene 31(43):4619\u20134629","journal-title":"Oncogene"},{"issue":"7","key":"3246_CR35","doi-asserted-by":"crossref","first-page":"e22739","DOI":"10.1371\/journal.pone.0022739","volume":"6","author":"M Cea","year":"2011","unstructured":"Cea M, Soncini D, Fruscione F, Raffaghello L, Garuti A, Emionite L, Moran E, Magnone M, Zoppoli G, Reverberi D, Caffa I, Salis A, Cagnetta A, Bergamaschi M, Casciaro S, Pierri I, Damonte G, Ansaldi F, Gobbi M, Pistoia V, Ballestrero A, Patrone F, Bruzzone S, Nencioni A (2011) Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells. PLoS One 6(7):e22739","journal-title":"PLoS One"},{"key":"3246_CR36","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1101\/gad.193501","volume":"15","author":"S Filleur","year":"2001","unstructured":"Filleur S, Volpert OV, Degeorges A, Voland C, Reiher F, Cl\u00e9zardin P, Bouck N, Cabon F (2001) In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects. Genes Dev 15:1373\u20131382","journal-title":"Genes Dev"},{"issue":"3","key":"3246_CR37","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/emm.2007.45","volume":"39","author":"JH Kang","year":"2007","unstructured":"Kang JH, Kim SA, Chang SY, Hong S, Hong KJ (2007) Inhibition of trichostatin A-induced antiangiogenesis by small-interfering RNA for thrombospondin-1. Exp Mol Med 39(3):402\u2013411","journal-title":"Exp Mol Med"},{"key":"3246_CR38","first-page":"6299","volume":"63","author":"Q Yang","year":"2003","unstructured":"Yang Q, Liu S, Tian Y, Salwen HR, Chlenski A, Weinstein J, Cohn SL (2003) Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma. Cancer Res 63:6299\u20136310","journal-title":"Cancer Res"},{"key":"3246_CR39","unstructured":"Zou Z, Zhang W, Young D, Gleave MG, Rennie P, Connell T, Connelly R, Moul J, Srivastava S, Sesterhenn I (2002) Maspin expression profile in human prostate cancer and in vitro induction of maspin expression by androgen ablation. Clin Cancer Res\u00a08:1172\u20131178"},{"key":"3246_CR40","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1158\/1078-0432.CCR-1002-03","volume":"10","author":"Z Khalkhali-Ellis","year":"2004","unstructured":"Khalkhali-Ellis Z, Christian A, Kirschmann DA, Edwards E, Rezaie-Thompson M, Vasef MA, Gruman L, Seftor REB, Norwood LE, Hendrix MJC (2004) Regulating the tumor suppressor gene maspin in breast cancer cells: a potential mechanism for the anticancer properties of tamoxifen. Clin Cancer Res 10:444\u2013449","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3246_CR41","first-page":"425","volume":"21","author":"SN Hong","year":"2009","unstructured":"Hong SN, Lee JK, Choe WH, Ha HY, Park K, Sung IK, Lee KT, Kim JJ, Rhee JC (2009) The effect of aberrant maspin expression on the invasive ability of pancreatic ductal adenocarcinoma cells. Oncol Rep 21(2):425\u2013430","journal-title":"Oncol Rep"},{"issue":"1","key":"3246_CR42","first-page":"86","volume":"7","author":"K Kashima","year":"2008","unstructured":"Kashima K, Ohike N, Mukai S, Sato M, Takahashi M, Morohoshi T (2008) Expression of the tumor suppressor gene maspin and its significance in intraductal papillary mucinous neoplasms of the pancreas. Hepatobiliary Pancreat Dis Int 7(1):86\u201390","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"3","key":"3246_CR43","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1158\/0008-5472.CAN-07-5714","volume":"68","author":"RF Hwang","year":"2008","unstructured":"Hwang RF, Moore T, Arumugam T, Ramachandran V, Amos KD, Rivera A, Ji B, Evans DB, Logsdon CD (2008) Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res 68(3):918\u2013926","journal-title":"Cancer Res"},{"issue":"6","key":"3246_CR44","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.3892\/or_00001026","volume":"24","author":"K Yamanegi","year":"2010","unstructured":"Yamanegi K, Yamane J, Kobayashi K, Kato-Kogoe N, Ohyama H, Nakasho K, Yamada N, Hata M, Nishioka T, Fukunaga S, Futani H, Okamura H, Terada N (2010) Sodium valproate, a histone deacetylase inhibitor, augments the expression of cell-surface NKG2D ligands, MICA\/B, without increasing their soluble forms to enhance susceptibility of human osteosarcoma cells to NK cell-mediated cytotoxicity. Oncol Rep 24(6):1621\u20131627","journal-title":"Oncol Rep"},{"issue":"3","key":"3246_CR45","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"T Chou","year":"2006","unstructured":"Chou T (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58(3):621\u2013681","journal-title":"Pharmacol Rev"},{"issue":"5","key":"3246_CR46","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nrclinonc.2013.42","volume":"10","author":"N Azad","year":"2013","unstructured":"Azad N, Zahnow CA, Rudin CM, Baylin SB (2013) The future of epigenetic therapy in solid tumours-lessons from the past. Nat Rev Clin Oncol 10(5):256\u2013266","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"3246_CR47","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.pharmthera.2013.03.010","volume":"139","author":"L Adwan","year":"2013","unstructured":"Adwan L, Zawia NH (2013) Epigenetics: a novel therapeutic approach for the treatment of Alzheimer\u2019s disease. Pharmacol Ther 139(1):41\u201350","journal-title":"Pharmacol Ther"},{"issue":"4","key":"3246_CR48","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1253\/circj.CJ-09-0580","volume":"74","author":"YK Cho","year":"2010","unstructured":"Cho YK, Eom GH, Kee HJ, Kim HS, Choi WY, Nam KI, Ma JS, Kook H (2010) Sodium valproate, a histone deacetylase inhibitor, but not captopril, prevents right ventricular hypertrophy in rats. Circ J 74(4):760\u2013770","journal-title":"Circ J"},{"key":"3246_CR49","doi-asserted-by":"crossref","unstructured":"Wang B, Yang R, Wu Y, Li H, Hu Z, Chen Y, Zou S (2013) Sodium valproate inhibits the growth of human cholangiocarcinoma in vitro and in vivo. Gastroenterol Res Pract 2013:374593","DOI":"10.1155\/2013\/374593"},{"key":"3246_CR50","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1476-4598-9-80","volume":"9","author":"S Sch\u00fcler","year":"2010","unstructured":"Sch\u00fcler S, Fritsche P, Diersch S, Arlt A, Schmid RM, Saur D, Schneider G (2010) HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells. Mole Cancer 9:80","journal-title":"Mole Cancer"},{"issue":"6","key":"3246_CR51","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1089\/cbr.2009.0629","volume":"24","author":"X Chen","year":"2009","unstructured":"Chen X, Wong P, Radany E, Wong JY (2009) HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells. Cancer Biother Radiopharm 24(6):689\u2013699","journal-title":"Cancer Biother Radiopharm"},{"key":"3246_CR52","doi-asserted-by":"crossref","first-page":"14935","DOI":"10.3390\/molecules181214935","volume":"18","author":"H An","year":"2013","unstructured":"An H, Xue Y, Shen Y, Du Q, Hu B (2013) Sodium valproate induces cell senescence in human hepatocarcinoma cells. Molecules 18:14935\u201314947","journal-title":"Molecules"},{"key":"3246_CR53","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1212\/WNL.0b013e31822f02e1","volume":"77","author":"M Weller","year":"2007","unstructured":"Weller M, Gorlia T, Cairncross JG, Van Den Bent MJ, Mason W, Belanger K, Brandes AA, Bogdahn U, Macdonald DR, Forsyth P, Rossetti AO, Lacombe D, Mirimanoff RO, Vecht CJ, Stupp R (2007) Prolonged survival with valproic acid use in the EORTC\/NCIC temozolomide trial for glioblastoma. Neurology 77:1156\u20131164","journal-title":"Neurology"},{"key":"3246_CR54","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1182\/blood-2007-03-078576","volume":"110","author":"AO Soriano","year":"2007","unstructured":"Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, Cortes J, Wierda WG, Ouzounian S, Quezada A, Pierce A, Estey EH, Issa JPJ, Kantarjian HM, Garcia-Manero G (2007) Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 110:2302\u20132308","journal-title":"Blood"},{"issue":"3","key":"3246_CR55","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2174\/138945010790711923","volume":"11","author":"J Hrebackova","year":"2010","unstructured":"Hrebackova J, Hrabeta J, Eckschlager T (2010) Valproic acid in the complex therapy of malignant tumors. Curr Drug Targets 11(3):361\u2013379","journal-title":"Curr Drug Targets"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-014-3246-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11033-014-3246-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-014-3246-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T03:16:35Z","timestamp":1559358995000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11033-014-3246-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,5]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["3246"],"URL":"https:\/\/doi.org\/10.1007\/s11033-014-3246-y","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,5]]}}}